Additionally, the combination of TMZ and RGD4C/AAVP‐Grp78‐HSVtk/GCV administered systemically elicited strong anti‐tumor activity against intracranial glioblastoma established in vivo from GBM cell lines and primary GBM, and in both immunodeficient and immunocompetent mice. Here, HSPA5 is linked to glioblastoma.